We are joined by Patrick Schrauwen at the ADA 2019 conference in San Francisco to discuss his symposium on circadian rhythmicity of skeletal muscle metabolism and its role in insulin resistance in humans, which is being presented at this year’s meeting.
Filmed at the American Diabetes Association (ADA) annual meeting 2019, San Francisco, USA.
1. What was the rationale for studying the effect of circadian rhythm on skeletal muscle insulin sensitivity? (0:05)
2. What have we learned from these studies? (0:38)
3. What are the implications of this for whole-body insulin resistance? (1:17)
4. How can these findings be used to improve the management of shift workers with type 2 diabetes? (1:48)
5. What further studies are planned? (2:44)
Patrick Schrauwen has no conflicts of interest to declare in relation to this video.
touchENDO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Diabetes
Andrew Boulton, IDF 2021: Anticipated Congress Highlights
It was a pleasure to meet with IDF President, Prof. Andrew Boulton (University of Manchester, UK) ahead of this year’s virtual meeting to discuss anticipated congress highlights and the relationship between COVID-19 and diabetes. Questions What do you expect to be the highlights of this year’s IDF Congress? (0:20) What have we learned about the […]
IDF Virtual 2021 – Diabetes Complications and Covid-19
The International Diabetes Federation will organise a Virtual Congress on December 6-11, 2021. It will feature the latest research on diabetes complications and sessions dedicated to COVID-19 and diabetes, the centenary of insulin and the IDF Diabetes Atlas 10th Edition. Discover the Congress at https://idf2021.org
Matthew Budoff, ENDO 2021: Findings from a Substudy of the VERTIS CV Trial – Ertugliflozin for T2DM & ASCVD
We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881). ‘Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!